Nektar Therapeutics (NKTR) Earning Very Favorable Press Coverage, Accern Reports

News stories about Nektar Therapeutics (NASDAQ:NKTR) have been trending very positive on Wednesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a news impact score of 0.69 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 80 out of 100, meaning that recent press coverage is likely to have an effect on the stock’s share price in the near future.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Several analysts have recently commented on the company. ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Roth Capital set a $31.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, May 22nd. Jefferies Group LLC reduced their target price on Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Aegis restated a “buy” rating and issued a $27.00 target price on shares of Nektar Therapeutics in a research note on Wednesday, May 10th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $29.00 target price on shares of Nektar Therapeutics in a research note on Tuesday, April 11th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $25.25.

Nektar Therapeutics (NASDAQ:NKTR) traded up 3.80% during midday trading on Wednesday, hitting $18.85. The stock had a trading volume of 144,341 shares. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The stock has a 50 day moving average of $19.14 and a 200 day moving average of $16.37. The stock’s market cap is $2.92 billion.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.02. The firm had revenue of $24.73 million for the quarter, compared to analysts’ expectations of $29.43 million. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. The company’s revenue for the quarter was down 58.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.14) earnings per share. Analysts expect that Nektar Therapeutics will post ($1.19) EPS for the current fiscal year.

In related news, SVP Stephen K. Doberstein sold 1,701 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $19.55, for a total transaction of $33,254.55. Following the completion of the transaction, the senior vice president now directly owns 32,803 shares of the company’s stock, valued at $641,298.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher A. Kuebler sold 15,000 shares of the stock in a transaction dated Wednesday, April 5th. The stock was sold at an average price of $21.88, for a total transaction of $328,200.00. Following the transaction, the director now directly owns 50,500 shares of the company’s stock, valued at $1,104,940. The disclosure for this sale can be found here. Insiders have sold 228,414 shares of company stock valued at $4,887,994 over the last three months. 5.44% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This report was published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.mideasttime.com/nektar-therapeutics-nktr-earning-very-favorable-press-coverage-accern-reports/1799003.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NKTR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.